Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
70710-1746-03 70710-1746 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
66993-0238-30 66993-0238 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
70710-1744-03 70710-1744 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70377-0083-11 70377-0083 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
59651-0544-15 59651-0544 DASATINIB DASATINIB 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct 28, 2010 In Use
00003-0852-11 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 3, 2009 Jan 26, 2011 In Use
00003-0852-22 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2008 In Use
59651-0547-15 59651-0547 DASATINIB DASATINIB 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
70771-1902-06 70771-1902 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
66993-0236-30 66993-0236 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
00003-0528-11 00003-0528 Dasatinib Sprycel 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 27, 2006 In Use
50419-0395-01 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Jul 31, 2019 In Use
50419-0395-72 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Mar 3, 2021 In Use
55513-0032-01 55513-0032 Darbepoetin alfa Aranesp 500.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Jun 7, 2006 In Use
55513-0011-01 55513-0011 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct 1, 2001 Nov 30, 2008 No Longer Used
55513-0005-04 55513-0005 Darbepoetin alfa Aranesp 100.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sep 11, 2006 In Use
55513-0111-01 55513-0111 Darbepoetin alfa Aranesp 300.0 ug/.6mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug 14, 2006 In Use
55513-0041-04 55513-0041 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Jul 23, 2003 Feb 28, 2009 No Longer Used
55513-0110-01 55513-0110 Darbepoetin alfa Aranesp 300.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug 14, 2006 In Use
55513-0015-01 55513-0014 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Aug 19, 2002 Apr 30, 2009 No Longer Used
55513-0021-04 55513-0021 Darbepoetin alfa Aranesp 40.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug 14, 2006 In Use
55513-0010-04 55513-0010 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct 1, 2001 Mar 31, 2009 No Longer Used

Found 11765 results — Export these results